Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection d
- PDF / 463,634 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 72 Downloads / 190 Views
ORIGINAL ARTICLE
Determination of risk factors for progression in patients with viable tumor at post‑chemotherapy lymph node dissection due to disseminated non‑seminomatous germ‑cell tumors Mesut Altan1 · Hakan Bahadır Haberal1 · Ahmet Aşçı1 · Ahmet Güdeloğlu1 · Ahmet Bülent Doğrul2 · Mustafa Sertaç Yazıcı1 · Bülent Akdoğan1 · Haluk Özen1 Received: 7 July 2020 / Accepted: 7 September 2020 © Japan Society of Clinical Oncology 2020
Abstract Background To assess the clinical variables that effect progression in patients with viable tumor after post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors. Methods We performed a retrospective analysis of 32 patients with viable tumor after PC-RPLND, operated between 1990 and 2016. Patients were categorized into 2 groups as favorable and non-favorable (intermedia and poor) according to International Germ Cell Consensus Classification (IGCCC). Tumor size was determined as the largest dimension of retroperitoneal mass. Clinical factors and adjuvant chemotherapy were evaluated to impact on recurrence free survival (RFS) and overall survival (OS). Results The median age of the patients and follow-up duration were 28.5 (17–51) years and 51.5 (4–253) months, respectively. 5-year RFS and OS were 57.8–66.8%, respectively. On univariate analysis, percentage of viable tumor, IGCCC risk group, primary site, second-line chemotherapy and surgical margin status were significant for RFS (p = 0.034, p = 0.002, p
Data Loading...
